Integrity Applications Appoints Luis J. Malavé to Board of Directors
Integrity Applications, Inc. (OTCQB: IGAP) has appointed Luis J. Malavé to its Board of Directors, effective immediately. Malavé, with over 30 years of experience in the MedTech industry, particularly in diabetes management, is expected to enhance the company's strategic direction. His previous leadership roles include President of EOFLOW CO. Ltd. and CEO of Palyon Medical. The company's GlucoTrack® device, a non-invasive glucose monitoring system, is aimed at the diabetes market and has received regulatory approvals in Europe and South Korea.
- Appointment of Luis J. Malavé expected to strengthen board expertise and company direction.
- Malavé's extensive experience in diabetes management could enhance GlucoTrack® market position.
- None.
WILMINGTON, Del. and ASHDOD, Israel, June 22, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (www.integrity-app.com) (OTCQB: IGAP), innovator of GlucoTrack®, a non-invasive device for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that Luis J. Malavé has been appointed to the Company’s Board of Directors, effective immediately.
“Luis’s impressive track record of working with medical device companies from product development to market expansion and high growth is ideally suited to Integrity,” said Paul V. Goode, PhD, member of the Board of Directors. “His expertise in the consumer diabetes space reflects our focus on developing Integrity into a dominant player in the diabetes management industry.”
Mr. Malavé brings more than 30 years of leadership experience in the MedTech industry, primarily in diabetes management, spanning all company stages, from private startups to large-cap publicly listed companies. He has extensive expertise in product development, operations, marketing, strategic partnerships, and US FDA regulatory strategy.
Mr. Malavé currently serves as President of EOFLOW CO. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump. Prior to that, Mr. Malavé was the President and CEO of Palyon Medical, maker of an implantable drug-delivery system that spun out from German medical-technology giant Fresenius SE. Prior to Palyon, he spent nearly a decade at insulin pump maker Insulet Corp., including as its Senior Vice President of Research, Development and Engineering, and as Chief Operating Officer. He also held various senior positions at Medtronic and MiniMed, overseeing product development of various diabetes management devices.
Mr. Malavé earned his Bachelor’s degree in Mathematics and Computer Science from the University of Minnesota, a Master’s degree in Software Engineering from the University of St. Thomas, and an MBA from the University of Maryland.
“I’ve spent most of my career focused on innovations in diabetes patient care and I have witnessed firsthand the positive impact medical technology can have on people’s lives,” said Mr. Malavé. “I look forward to working alongside my fellow board members and company management to advance this truly innovative technology that has the potential to help millions of people suffering from diabetes and prediabetes around the world.”
About GlucoTrack®
GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual’s glucose level in about a minute without finger pricking or any pain. GlucoTrack® features an ear clip with sensors that clips to the earlobe and measures the user’s glucose level using innovative and patented sensor technologies. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used to estimate HbA1c level using a proprietary algorithm. The device can also display glucose values graphically, enabling the user to monitor glucose levels over time. GlucoTrack® has received approvals for CE Mark in Europe and from the Ministry of Food and Drug Safety in South Korea for type 2 diabetes and prediabetes and is currently available in selected markets in Europe and Asia.
About Integrity Applications, Inc.
Integrity Applications, Inc. (OTCQB: IGAP) was founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit http://www.integrity-app.com/ and http://www.glucotrack.com.
Investor Contact:investors@integrity-app.com
Media Contact: media@integrity-app.com
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “expect”, “plan” and “will” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on April 13, 2021.
FAQ
Who is Luis J. Malavé and what is his role at Integrity Applications?
How will Luis J. Malavé's appointment impact Integrity Applications?
What is GlucoTrack® and how does it benefit diabetes patients?
What regulatory approvals has GlucoTrack® received?
